Saijo Ken, Imai Hiroo, Ouchi Kota, Sasaki Keiju, Yoshida Yuya, Kawamura Yoshifumi, Taniguchi Sakura, Kasahara Yuki, Komine Keigo, Shirota Hidekazu, Takahashi Masanobu, Ishioka Chikashi
Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Department of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, Japan.
Front Oncol. 2023 Aug 16;13:1230731. doi: 10.3389/fonc.2023.1230731. eCollection 2023.
Pembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear.
This study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients' characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed.
The 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and -9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= -0.41, p=0.0017; PFS: r=-0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤-45 was associated with better OS and PFS.
DpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.
含帕博利珠单抗的治疗方案是复发和转移性头颈部鳞状细胞癌（R/M HNSCC）的标准治疗方法。缓解深度（DpR）可预测多种实体癌患者的生存期；然而，其与接受含帕博利珠单抗方案治疗的R/M HNSCC患者生存结局的相关性仍不明确。
本研究纳入了66例在日本仙台东北大学医院接受含帕博利珠单抗方案一线治疗的R/M HNSCC患者。回顾了患者的特征、综合阳性评分、基线肿瘤大小、肿瘤反应、DpR、总生存期（OS）、无进展生存期（PFS）、PFS2和不良事件。分析了DpR与生存结局之间的相关性。
含帕博利珠单抗方案的1年总生存率和1年无进展生存率分别为69.4%和24.4%。缓解率为28.8%。肿瘤相对于基线的变化均值和中位数分别为5.1%和-9.0%。在相关性分析中，观察到肿瘤相对于基线的变化率与生存结局之间存在显著负相关（总生存期：r = -0.41，p = 0.0017；无进展生存期：r = -0.49，p < 0.001）。在多变量分析中，肿瘤变化≤-45的DpR与更好的总生存期和无进展生存期相关。
含帕博利珠单抗方案诱导的DpR可能是R/M HNSCC患者总生存期和无进展生存期的预测因素。
